Immunome (IMNM) EBITDA (2019 - 2026)

Immunome (IMNM) has 8 years of EBITDA data on file, last reported at -$59.3 million in Q1 2026.

• Quarterly EBITDA fell 32.92% year-over-year to -$59.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$238.8 million (down 9.48% YoY) and the FY2025 annual result came in at -$224.1 million, up 26.71% from the prior year.
• EBITDA grew to -$59.3 million in Q1 2026, from -$72.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$4.5 million in Q1 2023 to a low of -$132.3 million in Q1 2024.
• A 5-year average of -$43.3 million and a median of -$44.6 million in 2025 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2024 — EBITDA sank 2859.05% — and 2025, when it soared 66.26%.
• Tracing IMNM's EBITDA over 5 years: stood at -$7.8 million in 2022, then plunged by 1115.53% to -$94.7 million in 2023, then advanced by 12.34% to -$83.0 million in 2024, then advanced by 12.18% to -$72.9 million in 2025, then climbed by 18.57% to -$59.3 million in 2026.
• The last three EBITDA figures came in at -$59.3 million (Q1 2026), -$72.9 million (Q4 2025), and -$60.1 million (Q3 2025), per Business Quant data.